共 31 条
[2]
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
[J].
LANCET INFECTIOUS DISEASES,
2021, 21 (02)
:226-240
[4]
Choby JE, 2021, LANCET INFECT DIS, V21, P597, DOI 10.1016/S1473-3099(21)00194-8
[6]
Gu DX, 2018, LANCET INFECT DIS, V18, P37, DOI [10.1016/S1473-3099(17)30489-9, 10.1016/s1473-3099(17)30489-9]
[10]
In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study)
[J].
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS,
2019, 53 (02)
:177-184